Yang 2011.

Study characteristics
Methods	Study design: RCT Number randomized: 44; 19 to the exercise group and 21 to the control group Study start and stop dates: recruitment of participants took place between 2008 and 2009 Length of intervention: 12 weeks Length of follow‐up: to end of the intervention
Participants	Type cancer: breast cancer Cancer stage, n (%): exercise group: Stage I, 9 (47.4%); Stage II, 10 (52.6%); Stage IIIa, 0 (0%) control group: Stage I, 6 (28.6%); Stage II, 12 (57.1%); Stage IIIa, 3 (14.3%) Time since cancer diagnosis: not reported Time in active treatment: receiving 12 weeks of adjuvant chemotherapy postoperatively Inclusion criteria: women with postoperative Stage I to IIIA breast cancer receiving adjuvant chemotherapy during the study period ≥ 18 years old Eligibility criteria related to interest or ability, or both, to exercise: skeletomuscular deficits that would contraindicate a walking exercise program regularly engaged in > 1 session of moderate‐intensity exercise per week over the past 6 months Exclusion criteria: uncontrolled hypertension, diabetes mellitus, cardiac, or psychiatric illness Gender: female Current age, mean (SD) years: exercise group: 50.79 (7.05) years control group: 52.71 (8.11) years Age at cancer diagnosis: not reported Ethnicity/race: not reported Education level: not reported SES: not reported Employment status, employed, n (%): exercise group: 3 (15.8%) control group: 8 (38.1%) BMI, mean (SD) exercise group: 23.09 (3.32) control group: 24.37 (3.23) Comorbidities: none reported Past exercise history: not reported
Interventions	19 participants assigned to the exercise intervention, including: 12‐week home‐based walking program, developed using the American College of Sports Medicine Guidelines, and included walking starting 2 to 3 days after each chemotherapy session. The intervention included: 5 minutes' warm‐up 30 minutes' brisk walking 5 minutes' cool down Type exercise: (aerobic/anaerobic): aerobic Intensity of the experimental exercise intervention: moderate‐intensity brisk walking (60% to 80% of age‐adjusted maximal HR) Frequency: 3 times per week Duration of individual sessions: about 40 minutes Duration of exercise program: 12 weeks Total number of exercise sessions: 36 sessions Format: individual Facility: home Professionally led: not professionally led Adherence: adherence to the exercise intervention was about 77% (31.2 of 36) of the prescribed exercise sessions and 100% of the prescribed exercise intensity 21 participants assigned to control group, including: maintenance of their previous lifestyle for 12 weeks Contamination of control group: not reported
Outcomes	No primary outcome was identified. QoL outcomes included: symptom severity, assessed using the MDASI‐Taiwanese Version (MDASI‐T) symptoms interference with daily life, assessed using the MDASI‐T emotional distress, assessed using the POMS‐SF Other outcomes included: self‐reported physical activity level, assessed using the Seven‐Day Physical Activity Recall (7‐Day PAR) Outcomes were measured at baseline, 6 weeks, and 12 weeks: exercise group: n = 19 at baseline, n = 19 at 6 weeks, n = 19 at 12 weeks control group: n = 21 at baseline, n = 21 at 6 weeks, n = 21 at 12 weeks Subgroup analysis: none reported Adverse events: no participants experienced any adverse events related to home‐based exercise during the 12‐week study period
Notes	Country: Taiwan Funding: Taipei Medical University Hospital
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	The random location sequence was generated using a table of random numbers
Allocation concealment (selection bias)	Unclear risk	Whether the treatment assigned was concealed from study personnel and participants was not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	Owing to the nature of the intervention, it was not possible to conceal allocation to the intervention from the participants
Blinding of outcome assessment (detection bias) All outcomes	High risk	Allocation to the intervention was not concealed from the study personnel
Incomplete outcome data (attrition bias) All outcomes	High risk	44 women were randomly assigned to exercise or control groups and 40 women completed the trial. No information is provided on the 4 women who did not complete the trial
Selective reporting (reporting bias)	Low risk	There appears to be no selective reporting of outcomes
Other bias	Low risk	The trial appears to be free of other problems that could put it at a high risk of bias

6MWD: 6‐minute walk distance; 7‐Day PAR: Seven‐Day Physical Activity Recall; HR: heart rate; AFI: Attentional Functional Index; ALL: acute lymphoblastic leukemia; AML: acute myelogenous leukemia; BDI: Beck's Depression Inventory; BFI: Brief Fatigue Inventory; BMD: bone mineral density; BMI: body mass index; Borg RPE: Borg Rating of Perceived Exertion; CCS: Canadian Cancer Society; CES‐D: Center for Epidemiological Studies Depression scale; CML: chronic myeloid leukemia; CRP: C‐reactive protein; DXA: dual energy X‐ray absorptiometry; ECOG: Eastern Cooperative Oncology Group; EORTC: European Organization for Research and Treatment of Cancer; EPIC: Expanded Prostate Cancer Index Composite; ESES: Exercise Self‐efficacy Scale; EWB: emotional well‐being; FACIT‐F: Functional Assessment of Chronic Illness Therapy ‐ Fatigue; FACIT‐Sp: Functional Assessment of Chronic Illness Therapy ‐ Spiritual; FACT‐An: Functional Assessment of Cancer Therapy ‐ Anemia; FACT‐B: Functional Assessment of Cancer Therapy ‐ Breast; FACT‐Cog: Functional assessment of Cancer Therapy ‐ Cognitive Function; FACT‐ES: Functional Assessment of Cancer Therapy ‐ Endocrine symptoms; FACT‐F: Functional Assessment of Cancer Therapy ‐ Fatigue; FACT‐G: Functional Assessment of Cancer Therapy ‐ General; FACT‐P: Functional Assessment of Cancer Therapy ‐ Physical; FACT‐P: Functional Assessment of Cancer Therapy ‐ Prostate; FACT‐Sp: Functional Assessment of Cancer Therapy ‐ Spirituality; FAEPEX : Ao Fundo de Apoio ao Ensino, Pesquisa e Entenxao; FLIC: Functional Living Index for Cancer; FWB: functional well‐being; GLTEQ: Goldin Leisure Time Exercise Questionnaire; HADS: Hospital Anxiety and Depression Scale; HDC: high‐dose chemotherapy; HL: Hodgkin lymphoma; HR: heart rate; HRQoL: health‐related quality of life; HSCT: hematopoietic stem cell transplantation; ITT: intention‐to‐treat; LASA: Linear Analog Scales of Assessment; LHRHa: luteinizing hormone‐releasing hormone analogue; LOCF: last observation carried forward; LSI: Leisure Score Index; MANE: Morrow Assessment of Nausea and Emesis; MCS: mental component status; MDASI‐T: M.D. Anderson Symptom Inventory‐Taiwanese Version; MFI: Multidimensional Fatigue Inventory; MFSI‐SF: Multidimensional Fatigue Symptom Inventory Short Form; MMSE: Mini Mental Status Examination; MOS SF‐36: Medical Outcomes 36‐Item Short Form Health Survey; MVT: maximum voluntary torque; MWT: minute walk test; NCIC: National Cancer Institute of Canada; NHL: non‐Hodgkin lymphoma; NYHA: New York Heart Association; PANAS: Positive and Negative Affect Schedule; PCS: physical component status; PFS: Piper Fatigue Scale; POMS: Profile of Mood States; POMS‐SF; Profile of Mood State‐Short Form; PSA: prostate specific antigen; PSQI: Pittsburgh Sleep Quality Inventory; PWB: physical well‐being; QLQ: Quality of Life Questionnaire; QoL: quality of life; ROM: range of motion; rPAR‐Q: revised Physical Activity Readiness Questionnaire; SCFS: Schwartz Cancer Fatigue Scale; SCL: Symptom Check List; SPAQ: Scottish Physical Activity Questionnaire; SPSS Expectation Maximization; STAI: State‐Trait Anxiety Index; SWB: social/family well‐being; SWLS: Satisfaction with Life Scale; TOI‐An: Trial Outcome Index ‐ Anemia; UNICAMP: da Universidade Estadual de Campinas; VAS: visual analog scale; VO2max: maximal oxygen uptake; VYASA: Vivekananda Yoga Anusandhana Samsthana; WHO: World Health Organization; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index.